Compare PAR & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAR | CSTL |
|---|---|---|
| Founded | 1968 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Medical Specialities |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 887.7M | 806.3M |
| IPO Year | 1995 | 2019 |
| Metric | PAR | CSTL |
|---|---|---|
| Price | $14.52 | $25.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $36.00 | ★ $47.17 |
| AVG Volume (30 Days) | ★ 1.4M | 397.3K |
| Earning Date | 05-29-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $455,547,000.00 | $344,229,000.00 |
| Revenue This Year | $11.10 | $2.10 |
| Revenue Next Year | $11.31 | $12.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 30.16 | 3.66 |
| 52 Week Low | $15.44 | $14.59 |
| 52 Week High | $72.15 | $44.28 |
| Indicator | PAR | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 29.00 | 26.28 |
| Support Level | N/A | $21.77 |
| Resistance Level | $38.44 | $34.97 |
| Average True Range (ATR) | 1.54 | 1.38 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 19.58 | 7.96 |
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). The company's product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.